Regeneron Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (69)

Latest Posts

About This Stock More About This Stock
A Powerful Buy Signal
Article By: Marc Lichtenfeld
Saturday, September 12, 2020 4:29 PM EDT
Phase 2 trials are my favorite time to get involved in a biotech company. Phase 2 is often the most profitable time to be involved in a small cap biotech stock. Many times, Phase 2 results are positive.
In this article: PFE, CVM, CLDX, REGN, DCTH, MELA, DERM, NVCR
Read
E Market Mania
Article By: Vivian Lewis
Wednesday, August 19, 2020 8:10 PM EDT
Swiss Roche with Regeneron REGN will make 3.5 mn doses of a future virus jab.
In this article: BCE, GSK, RDY, RHHBY, REGN, AAPL, TEVA, TAK
Read
10 Best-Performing Stocks In Nasdaq ETF As Index Tops 11,000
Article By: Sweta Killa
Friday, August 7, 2020 1:38 PM EDT
Here are the 10 best-performing stocks in the ETF with their respective positions in the fund’s basket:
In this article: AMD, DXCM, MELI, REGN, AMZN, NVDA, TSLA, JD, PYPL, DOCU
Read
Jeff Bezos Sells More Than $3bn In Amazon Stock
Article By: Adam Vettese
Thursday, August 6, 2020 6:30 AM EDT
Amazon founder and CEO Jeff Bezos has sold more than $3bn worth of Amazon stock, after the company’s share price surged 36% in the past three months and 73% in the year-to-date.
In this article: BMY, TMUS, UBER, AMZN Also: BA, DIS, BHPBF, CCHBF, EVRZF, FNLPF, GLCNF, SAXPY, WIMHF, REGN, DIA, GLD, SPY, COMP, FB, TWTR, SPX, AAL, BITCOMP, NGLOY, POYYF
Read
Gold Passes $2,000 An Ounce For First Time In History As Investor Fear Grows
Article By: Adam Vettese
Wednesday, August 5, 2020 5:52 AM EDT
On Tuesday the price of gold passed $2,000 an ounce for the first time in history, driven by continued fears of the economic impact of the coronavirus pandemic, and rock-bottom bond yields.
In this article: NVAX, SQ, DIS, REGN, BP, SPX, DJI, GLCNF, GLD, BITCOMP
Read

PARTNER HEADLINES

Latest Tweets for $REGN

No tweets yet!

$REGN

Regeneron Pharmaceuticals’ Dupixent Has Multi-Billion-Dollar Potential: Polen Capital
David J. Tanner 1/31/2018 3:55:05 AM

Note it has only been approved in Japan. And only for those whom existing treatments are ineffective. So that's a MUCH smaller market. How small I don't know. But not enough to make me bite. $REGN

1 to 1 of 1 comments